Recombinant Human CD200R1 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human CD200R1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD200 R1 Fc Chimera is immobilized at 2 μg/mL (100 μL/well), the concentration of Recombinant Human CD200 Fc Chimera (Catalog # 2724-CD) that produces 50% of the optimal binding response is appoximately 2.5-15 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human CD200 R1 protein
  

  Human CD200 R1 (Ala27-Leu266) Accession # AAQ19772	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAQ19772
• N-terminal Sequence: Ala27
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: CD200R1
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 53.4 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 85-95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD200R1 Fc Chimera Protein, CF

• CD200 R1
• CD200 receptor 1
• CD200R1
• CD200RMOX2Rcell surface glycoprotein CD200 receptor 1
• Cell surface glycoprotein OX2 receptor 1
• cell surface glycoprotein receptor CD200
• CRTR2
• HCRTR2
• MOX2 receptor
• MOX2R
• OX2RCD200 cell surface glycoprotein receptor

Background

CD200 R1, also known as OX-2 receptor, is a 90 kDa transmembrane protein in the immunoglobulin superfamily (1-3). The standard human CD200 R1 cDNA encodes a 325 amino acid (aa) precursor that includes a 28 aa signal sequence, a 215 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 61 aa cytoplasmic domain. The ECD is composed of one Ig-like V-type domain and one Ig-like C2-type domain (4). Within the ECD, human CD200 R1 shares 56% aa sequence identity with mouse and rat CD200 R1. Alternate splicing of the human CD200 R1 mRNA generates four isoforms, two of which are truncated in the Ig-C2 domain and are likely secreted. The protein expressed here contains a mature region that is identical to that of the standard form. There is an N-terminal extension of 25 aa that, in the standard form, is part of the signal sequence. In human, a separate CD200 R12 gene encodes a protein that shares 81% ECD aa identity with CD200 R11. In mouse, at least four genes for CD200 R1-like molecules have been described (4‑6). CD200 R1 expression is restricted primarily to mast cells, basophils, macrophages, and dendritic cells (7 - 9), while its ligand, CD200, is widely distributed (10). Disruption of this receptor-ligand system by knockout of the CD200 gene in mice leads to increased macrophage number and activation and predisposition to autoimmune disorders (11). Association of CD200 with CD200 R1 takes place between their respective N-terminal Ig-like domains (12). The capacity of CD200 R1-like molecules to interact with CD200 is controversial (5, 13). CD200 R1 propagates inhibitory signals despite its lacking a cytoplasmic ITIM (immunoreceptor tyrosine-based inhibitory motif) (8, 9, 14, 15) CD200 R1-like molecules, in contrast, are potentially activating receptors by means of their association with DAP12 (4, 6).

1. Rosenblum, M.D. et al. (2006) J. Dermatol. Sci. 41:165.
2. Gorczynski, R.M. (2005) Curr. Opin. Invest. Drugs 6:483.
3. Barclay, A.N. et al. (2002) Trends Immunol. 23:285.
4. Wright, G.J. et al. (2003) J. Immunol. 171:3034.
5. Hatherley, D. et al. (2005) J. Immunol. 175:2469.
6. Voehringer, D. et al. (2004) J. Biol. Chem. 279:54117.
7. Shiratori, I. et al. (2005) J. Immunol. 175:4441.
8. Cherwinski, H.M. et al. (2005) J. Immunol. 174:1348.
9. Fallarino, F. et al. (2004) J. Immunol. 173:3748.
10. Wright, G.J. et al. (2001) Immunology 102:173.
11. Hoek, R.M. et al. (2000) Science 290:1768.
12. Hatherley, D. and A.N. Barclay (2004) Eur. J. Immunol. 34:1688.
13. Gorczynski, R. et al. (2004) J. Immunol. 172:7744.
14. Jenmalm, M.C. et al. (2006) J. Immunol. 176:191.
15. Zhang, S. et al. (2004) J. Immunol. 173:6786.

Publications for CD200R1 (3414-CD)(1)

Publication using 3414-CD

• SC Garrett-Th, A Massimi, EV Fedorov, JB Bonanno, L Scandiuzzi, B Hillerich, RD Seidel, JD Love, SJ Garforth, C Guha, SC Almo Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex PLoS ONE, 2020-06-04;15(6):e0233578. 2020-06-04 [PMID: 32497097] (Bioassay, Human)

Bioinformatics

• Gene Symbol: CD200R1
• Uniprot:
  • AAQ19772()